Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Interest & Investment Income (2016 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Interest & Investment Income for 7 consecutive years, with $1.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Interest & Investment Income fell 81.83% to $1.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $10.3 million, a 49.16% decrease, with the full-year FY2025 number at $10.3 million, down 49.16% from a year prior.
  • Interest & Investment Income was $1.7 million for Q4 2025 at Iovance Biotherapeutics, up from $1.2 million in the prior quarter.
  • In the past five years, Interest & Investment Income ranged from a high of $9.6 million in Q4 2024 to a low of $1.2 million in Q3 2025.
  • A 3-year average of $3.7 million and a median of $3.3 million in 2024 define the central range for Interest & Investment Income.
  • Peak YoY movement for Interest & Investment Income: surged 207.09% in 2024, then plummeted 81.83% in 2025.
  • Iovance Biotherapeutics' Interest & Investment Income stood at $3.1 million in 2023, then soared by 207.09% to $9.6 million in 2024, then tumbled by 81.83% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Interest & Investment Income are $1.7 million (Q4 2025), $1.2 million (Q3 2025), and $4.1 million (Q2 2025).